Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion

Industry Insight by 2FIRSTS, edited by Sophia
Apr.08.2024
Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion
EVO NXT Interview: 2FIRSTS discussed nicotine pouch market trends with NNPA.EU leaders Jonas Lundqvist and Rebert Casinge.

Recently, at the EVO NXT tobacco exhibition in Spain, 2FIRSTS engaged in a deep discussion with Jonas Lundqvist, CEO of the Nordic Nicotine Pouches Alliance (NNPA.EU), and Robert Casinge, Editor-in-Chief of pouchforum.eu, about the trends, regulations, and future development of the nicotine pouch market. The NNPA.EU, headquartered in Brussels, has been studying the trends in oral tobacco consumption for 20 years.

 

Interview with NNPA.EU: EU Nicotine Pouch Users on the Rise, Market Projected to Reach €2.1 Billion
Jonas Lundqvist (left) and Robert Casinge (right) | Image source: 2FIRSTS

 

EU Market is Experiencing Robust Growth

 

According to data, the number of nicotine pouch users in the European Union is steadily increasing, reaching 2.6 million. The adult usage rate is 0.7%, with an annual growth rate of 7%. This trend indicates a continued interest and acceptance among consumers for this product. Nicotine pouches overlap with traditional cigarettes, especially among users seeking reduced harm alternatives.

 

In terms of market, the European Union has over 90 nicotine pouch brands, with main producing countries including Sweden, Denmark, Hungary, Poland, Italy, and the Czech Republic. The majority of sales channels are offline, accounting for 68%, while online sales make up 32%. Forecasts indicate that by 2027, the nicotine pouch market value is expected to reach 15-16 billion euros, potentially even reaching 21 billion euros, provided that the policy environment remains favorable.

 

Regulatory Challenges to be Addressed

 

However, the nicotine pouch market also faces regulatory challenges. While most European Union countries consider it a general consumer product, there are still some countries that classify it as a tobacco product or a medicine/food product.

 

For example, the number of snus (nicotine pouch) users in Sweden is similar to the EU average, but the proportion of cigarette smokers is lower (5-6%), especially among young people, leading the World Health Organization to consider Sweden a smoke-free country. However, 9 EU countries classify nicotine pouch as a tobacco-related product, 4 as a medicine/food, and most countries (14) consider it a general consumer product.

 

As the host country of this exhibition, Spain's policies are unclear, while Bulgaria and Greece have specific tax policies on nicotine pouches.

 

Although the European Union has not yet established specific regulations, signs indicate that it may include it in the Tobacco Products Directive in the future. Of particular note is that Nordic governments are actively strengthening regulation of nicotine pouches, with Finland recently legalizing them as smoking cessation aids and imposing restrictions on sales to curb illegal smuggling and sales.

 

Public Attitudes Divide, Caution Needed in Product Innovation

 

There is a certain amount of disagreement in public attitudes. A public opinion consultation by the European Commission showed that the public and health organizations generally support nicotine pouches as a smoking cessation tool, but regulators are cautious about their health impacts. For example, it is deemed acceptable for each nicotine pouch to contain 20mg of nicotine, and products with high nicotine content should not exceed 50mg.

 

The popularity of nicotine pouches is mainly due to their simple and convenient nature - no charging or e-liquid is required, making them easy to carry and suitable for replacing traditional cigarettes. However, the issues of product flavor and market demand should not be overlooked. Manufacturers need to be cautious of flavors that may appeal to children, and strengthen the control and balance of chemical ingredients.

 

Therefore, although the nicotine pouch market is showing strong momentum in growth, regulatory disputes and public concerns are still ongoing. The key to future development lies in changes in the policy environment and the improvement of market innovation capabilities.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia will place e-cigarettes and related nicotine products under its “strategic goods” framework from August 20, 2026. According to TVP World’s report published on August 19, the newly listed items include e-cigarettes, electronic smoking devices, vape liquids and nicotine salts. Individuals who illegally move these products across Russia’s customs border or its state border with other Eurasian Economic Union (EAEU) members could face up to five years in prison if shipment values exceed 100,000 rubles (about €1,000), provided all elements of a criminal offence are established.
Aug.20
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23